ABSTRACT
OBJECTIVE: The aim of the study was to evaluate the diagnostic efficiency of ground-glass opacity (GGO) for coronavirus disease 2019 (COVID-19) in suspected patients. MATERIALS AND METHODS: In this systematic review and meta-analysis, PubMed, Embase, Cochrane Library, Scopus, Web of Science, CNKI, and Wanfang databases were searched from November 01, 2019 to November 29, 2020. Studies providing the diagnostic test accuracy of chest computed tomography (CT) and description of detailed CT features for COVID-19 were included. Data were extracted from the publications. The sensitivity, specificity, and summary receiver operating characteristic curves were pooled. Heterogeneity was detected across included studies. RESULTS: Eleven studies with 1618 cases were included. The pooled sensitivity, specificity and area under the curve were 0.74 (95% confidence interval [CI], 0.61–0.84), 0.52 (95% CI, 0.33–0.70), and 0.70 (95% CI, 0.66–0.74), respectively. There was obvious heterogeneity among included studies (P < 0.05). Differences in the study region, inclusion criteria, research quality, or research methods might have contributed to the heterogeneity. The included studies had no significant publication bias (P > 0.1). CONCLUSIONS: COVID-19 was diagnosed not only by GGO with a medium level of diagnostic accuracy but also by white blood cell counts, epidemic history, and revers transcription-polymerase chain reaction testing.
ABSTRACT
OBJECTIVES: The chest CT findings that can distinguish patients with corona virus disease 2019 (COVID-19) from those with clinically suspected COVID-19 but subsequently found to be COVID-19 negative have not previously been described in detail. The purpose of this study was to determine the distinctions among patients with COVID-19 by comparing the imaging findings of patients with suspected confirmed COVID-19 and those of patients initially suspected to have COVID-19 who were ultimately negative for the disease. METHODS: 28 isolated suspected in-patients with COVID-19 were enrolled in this retrospective study from January 22, 2020 to February 6, 2020. 12 patients were confirmed to have positive severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) RNA results, and 16 patients had negative results. The thin-section CT imaging findings and clinical and laboratory data of all the patients were evaluated. RESULTS: There were no significant differences between the 12 confirmed COVID-19 (SARS-Cov-2-positive) patients and 16 SARS-CoV-2-negative patients in epidemiology and most of the clinical features or laboratory data. The CT images showed that the incidence of pure/mixed ground-glass opacities (GGOs) was not different between COVID-19 and SARS-CoV-2-negative patients [9/12 (75.0%) vs 10/16 (62.5%), p = 0.687], but pure/mixed GGOs in the peripheral were more common in patients with COVID-19 [11/12 (91.7%) vs 6/16 (37.5%), p = 0.006]. There were no significant differences in the number of lesions, bilateral lung involvement, large irregular/patchy opacities, rounded opacities, linear opacities, crazy-paving patterns, halo signs, interlobular septal thickening or air bronchograms. CONCLUSIONS: Although peripheral pure/mixed GGOs on CT may help distinguish patients with COVID-19 from clinically suspected but negative patients, CT cannot replace RT-PCR testing. ADVANCES IN KNOWLEDGE: Peripheral pure/mixed GGOs on-chest CT findings can be helpful in distinguishing patients with COVID-19 from those with clinically suspected COVID-19 but subsequently found to be COVID-19 negative.